Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]

Core Viewpoint - Company has received a medical device registration certificate from the Beijing Drug Administration for the Kappa Light Chain (K-LC) assay kit, which is used for the quantitative measurement of K-LC in human serum, enhancing its product line in the in vitro diagnostic biochemical sector [1] Group 1 - The newly certified product is specifically designed for use with Abbott's closed-channel instruments, indicating a strategic partnership that may enhance market competitiveness [1] - This product expansion is expected to improve the company's core competitiveness and market expansion capabilities, potentially leading to positive impacts on future operations [1] - Actual sales performance of the product will depend on future marketing effectiveness, and the company currently cannot predict its impact on future financial performance [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-112 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司 董事会 2025年11月27日 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 轻链κ测定试剂盒 （免疫比浊法） | 京 械 注 准 20252400941 | Ⅱ | 自批准之日起有效期 至 2030 年 11 月 23 日 | 本试剂盒用于体外定量 测定人血清中轻链κ （κ-LC）的含量。 | 上述产品为雅培仪器封闭通道配套专用试剂，丰富了公司在体外诊断生 化细分领域产品线的品种，有利 ...

Core Viewpoint - The company, Jiukang Biotechnology, announced a temporary suspension of the conversion of its convertible bonds due to the implementation of the second mid-term equity distribution for 2025, which will resume on November 27, 2025 [1] Group 1 - Jiukang Biotechnology's convertible bonds (code: 123150; abbreviation: Jiukang Convertible Bonds) will be suspended from conversion from November 19, 2025, until the equity registration date on November 26, 2025 [1] - The resumption of the bond conversion will take place on the first trading day after the equity registration date, specifically on November 27, 2025 [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、债券代码：123150 ；债券简称：九强转债 2、恢复转股时间：自 2025 年 11 月 27 日起恢复转股 | 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-111 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司（以下简称"公司"）因实施 2025 年第二次中期 权益分派，根据《北京九强生物技术股份有限公司创业板向不特定对象发行可转换公 司债券募集说明书》及相关规定，公司可转换公司债券（债券代码：123150 ；债券 简称：九强转债 ）自 2025 年 11 月 19 日至本次权益分派股权登记日（2025 年 11 月 26 日）止暂停转股。具体内容详见公司于 2025 年 11 月 17 日披露的《关于实施权益 分派期间九强转债暂停转股的提示性公告》（公告编号：2025-106）。 北京九强生物技术股份有限公司 关于九强转债恢复转股的提示性公告 根据规定，"九强转债" 将于本次权益 ...

股票代码：300406 股票简称：九强生物 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 公开发行可转换公司债券 第四次临时受托管理事务报告 （2025 年度） 债券受托管理人 二〇二五年十一月 重要声明 本报告依据《公司债券发行与交易管理办法》《北京九强生物技术股份有限 公司与中国国际金融股份有限公司关于向不特定对象发行可转换公司债券之债 券受托管理协议》（以下简称"《受托管理协议》"）《北京九强生物技术股份 有限公司创业板向不特定对象发行可转换公司债券募集说明书》（以下简称"《募 集说明书》"）等相关规定，由本期债券受托管理人中国国际金融股份有限公司 （以下简称"中金公司"）编制。中金公司对本报告中所包含的从上述文件中引 述内容和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性和 完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相关 事宜做出独立判断，而不应将本报告中的任何内容据以作为中金公司所作的承诺 或声明。在任何情况下，投资者依据本报告所进行的任何作为或不作为，中金公 司不承担任何责任。 1 中金公司作为 20 ...

Core Insights - The stock price of Jiukang Bio remained unchanged on November 20, with a trading volume of 32.39 million yuan [1] - The company experienced a financing net purchase of 776,100 yuan on the same day, indicating low financing activity compared to historical levels [1] Financing and Margin Trading - On November 20, Jiukang Bio had a financing purchase of 5.29 million yuan, with a total financing balance of 169 million yuan, representing 2.15% of its market capitalization [1] - The financing balance is below the 30th percentile of the past year, indicating a low level of financing [1] - In terms of margin trading, there were no shares repaid, but 700 shares were sold short, amounting to 9,366 yuan at the closing price [1] - The short selling balance stood at 115,740 yuan, which is above the 80th percentile of the past year, indicating a high level of short selling [1] Financial Performance - For the period from January to September 2025, Jiukang Bio reported a revenue of 1.012 billion yuan, a year-on-year decrease of 18.24% [2] - The net profit attributable to shareholders was 272 million yuan, down 27.03% year-on-year [2] Shareholder Information - As of September 30, 2025, the number of Jiukang Bio's shareholders was 18,100, a decrease of 2.48% from the previous period [2] - The average number of circulating shares per shareholder increased by 2.54% to 23,502 shares [2] - Cumulatively, Jiukang Bio has distributed 1.33 billion yuan in dividends since its A-share listing, with 701 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF held 8.3446 million shares, a decrease of 1.4085 million shares from the previous period [3]

Core Insights - The Biotech Index (970038) closed at 2182.31 points, down 0.94%, with a trading volume of 13.462 billion yuan and a turnover rate of 1.08% [1] - Among the index constituents, 7 stocks rose while 42 stocks fell, with Xinlitai leading the gainers at 0.83% and Hualan Biological leading the decliners at 5.98% [1] Index Constituents Summary - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 12.58%, latest price at 204.81, and a decline of 0.92% [1] - Changchun High-tech (sz000661) with a weight of 4.87%, latest price at 102.32, and a decline of 0.27% [1] - Shimeiao (sz002252) with a weight of 4.74%, latest price at 6.70, and a decline of 0.30% [1] - Kanglong Chemical (sz300759) with a weight of 4.55%, latest price at 29.16, and a decline of 1.22% [1] - Tigermed (sz300347) with a weight of 4.54%, latest price at 52.37, and a decline of 2.44% [1] - Shenzhen Technology (sz000021) with a weight of 4.16%, latest price at 23.90, and a decline of 1.77% [1] - Muyuan Foods (sz002714) with a weight of 3.62%, latest price at 48.45, and a decline of 0.31% [1] - Lepu Medical (sz300003) with a weight of 3.19%, latest price at 16.11, and a decline of 1.29% [1] - Aimeike (sz300896) with a weight of 3.16%, latest price at 155.51, and an increase of 0.58% [1] - Yuyue Medical (sz002223) with a weight of 3.07%, latest price at 35.28, and a decline of 0.20% [1] Capital Flow Analysis - The Biotech Index constituents experienced a net outflow of 1.382 billion yuan from major funds, while retail investors saw a net inflow of 1.358 billion yuan [1] - Notable capital flows include: - Aimeike (sz300896) had a net inflow of 26.5772 million yuan from major funds, but a net outflow from retail investors of 20.4422 million yuan [2] - Changchun High-tech (sz000661) saw a net inflow of 8.8418 million yuan from major funds, with a slight net inflow from retail investors of 186.25 thousand yuan [2] - Other stocks like Furuisi (sz300049) and Yuyue Medical (sz002223) also showed mixed capital flows with significant net outflows from retail investors [2]

Core Viewpoint - Jiukang Bio announced its second interim profit distribution plan for 2025, detailing a cash dividend distribution to shareholders [1] Group 1: Dividend Distribution - The company will distribute a cash dividend of 2.00 RMB per 10 shares to all shareholders, amounting to a total cash dividend of 116,552,908.80 RMB (including tax) [1] - The distribution is based on a total share count of 582,764,544 shares after excluding 3,544,084 shares held in the company's repurchase account [1] - The record date for the dividend is set for November 26, 2025, with the ex-dividend date on November 27, 2025 [1]

Core Viewpoint - Jiukang Bio announced a reduction in the conversion price of its convertible bonds from 16.68 yuan per share to 16.48 yuan per share, effective from November 27, 2025 [1] Group 1 - The adjustment in the conversion price reflects a strategic decision by the company to enhance the attractiveness of its convertible bonds [1] - The new conversion price will take effect on the ex-dividend date, indicating a planned timeline for the adjustment [1]